|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Disease activity and disabil- ity in children with juvenile idiopathic arthritis one year follow- ing presentation to pediatric rheumatology: results from the Childhood Arthritis Prospective Study 显示文摘 | Hyrich KL Lal SD Foster HE | 2010 | Rheumatology (Ox- ford)2010，49，1： | 1 |
| 2 | Drug-speclfic risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheu- matology biologics register (BSRBR) 显示文摘 | DIXON WG HYRICH KL WATSON KD | 2010 | Ann Rheum Dis2010，69，3： | 1 |
| 3 | 难治性类风湿关节炎的临床特点:一项国际问卷调查研究显示文摘目的尽管按照目前欧洲抗风湿联盟(EULAR)的推荐对类风湿关节炎(rheumatoid arthritis,RA)患者进行治疗,难治性RA患者的临床症状却仍然没有得到完全控制,目前EULAR指南主要关注的是RA的早期治疗和药物治疗。本研究的目的在于分析难治性RA患者的临床特点,以及在患者管理中需要探索然而现有EULAR指南并未涉及的问题。方法对多个国家的风湿科医生进行问卷调查,分析难治性RA的临床特点。问卷包括多选题以及开放性问题,从开放性问题的回答中发现需要进一步阐明的问题以及现有EULAR指南需要增加的内容。结果410名受访者完成了调查问卷,关于难治性RA的特点:50%受访者认为基于28个关节评估的疾病活动评分(disease activity score assessing 28 joints,DAS28)>3.2或存在疾病活动的征象;42%受访者认为疲劳是其特点;48%认为至少两种传统合成改变病情抗风湿药(DMARDs)以及使用至少两种生物制剂或靶向合成DMARDs治疗失败;89%认为糖皮质激素不能减量到5 mg/天或泼尼松不能减量到10 mg/天或同等剂量的其他激素。另外,现有EULAR指南中应增加合并症和关节外表现的干预以及多种药物联合治疗等重要内容。结论目前风湿科医生对难治性RA的定义有很大争议。难治性RA患者的很多重要问题目前EULAR指南中均没有涉及。 | Nadia MT Roodenrijs Maria J H de Hair Marlies C van der Goes Johannes WG Jacobs Paco MJ Welsing Désirée van der Heijde Daniel Aletaha Maxime Dougados Kimme L Hyrich Iain B McInnes Ulf Mueller-Ladner Ladislav Senolt Zoltan Szekanecz Jacob Mvan Laar Nagy Gyorgy 黄艳荣(译) 张卓莉(审校) | 2019 | 英国医学杂志中文版2019，22，2： | 1 |
| 4 | Comparison oftheresponse to infliximab or etanercept monotherapy with theresponse tocotherapy with methotrexate or another disease -modifyingantirheumatic drug in patients with rheumatoid ar-thritis :results fromthe British Society for Rheumatology Bio-logies Register 显示文摘 | Hyrich KL Symmons DP Watson KD’ | 2006 | Arthritis Rheum2006，54，6： | 1 |
| 5 | Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment:updated results from the british society for rheumatology biologics register with special empha显示文摘 | Galloway J B Hyrich K L Mercer L K | | 0，，02： | 1 |
| 6 | Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis显示文摘 | Potter C Hyrich KL Tracey A | 2009 | Ann Rheum Dis2009，68，： | 1 |
| 7 | Association of the tumour necrosis factor - 308 variant wilLh differential response to anti - TNF agents in the treatment of rheumatoid arthritis 显示文摘 | MAXWELL J R POTTER C HYRICH I~ L | 2008 | Hum Mol Genet2008，17，22： | 1 |
| 8 | Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety显示文摘 | Hyrich KL Silman AJ Watson KD | 2004 | Ann Rheum Dis2004，63，： | 1 |
| 9 | Predictors of re- sponse to anti -TNF -alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register显示文摘 | HYRICH K L WATSON K D SILMAN A J | 2006 | Rheumatology2006，45，12： | 1 |
| 10 | Biologic therapies and pregnancy:the story so far显示文摘 | Hyrich KL Verstappen SM | 2013 | Rheumatology(Oxford)2013，，： | 1 |
| 11 | Drag-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti- TNF therapy: results from the British Society for Rheumatology Biologies Register (BSRBR)显示文摘 | Dixon WG Hyrich KL Watsoo KD | 2010 | Ann Rheum Dis2010，69，3： | 1 |
| 12 | Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to pediatric rheumatology:results from the Childhood Arthritis Prospective Study 显示文摘 | Hyrich KL Lal SD Foster HE | 2010 | Rheu- matology ( Ox · ford)2010，49，1： | 1 |
| 13 | Association of the tumour necro- sis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis显示文摘 | Maxwell JR Potter C Hyrich KL | 2008 | Hum Mol Genet2008，17，22： | 1 |
| 14 | Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated resuhs from the British Society for Rheumatology Biologics Register with special emphasis on risks in the ehterly 显示文摘 | GALLOWAY J B HYRICH K L MERCER L K | 2010 | Rheumatology2010，31，1： | 1 |
| 15 | Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthri- tis: results from the British Society for Rheumatology Biologics Register显示文摘 | Hyrich KL Watson KD Silman A J | 2006 | Rheumatology ( Oxford )2006，45，12： | 1 |
| 16 | Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register 显示文摘 | Hyrich K L Symmons D P Watson K D | 2006 | Arthritis Rheum2006，54，6： | 1 |
| 17 | Predictors of Response to Anti-TNF- Therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register显示文摘 | K L Hyrich K D Watson A J Silman | 2006 | Rheumatotogy2006，45，16： | 1 |
| 18 | Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy:results from the British Society for Rheumatology Biologics Register (BSRBR)显示文摘 | Dixon WG Hyrich KL Watson KD | | 0，，03： | 1 |
| 19 | Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis:results from a large UK national cohort study显示文摘 | Hyrich KL Lunt M Watson KD | 2007 | Arthritis Rheum2007，56，1： | 1 |
| 20 | Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)显示文摘 | Dixon W G Hyrich K L Watson K D | 2010 | Ann Rheum Dis2010，69，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员